Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Sep 15;12(18):2919-20.
doi: 10.4161/cc.26175. Epub 2013 Aug 23.

Interfering with type I interferon: a novel approach to purge persistent viral infection

Elizabeth B Wilson  1 , David G Brooks
Affiliations
Editorial

Interfering with type I interferon: a novel approach to purge persistent viral infection

Elizabeth B Wilson et al. Cell Cycle. .
No abstract available

Keywords: HIV; LCMV; chronic; hepatitis virus; immune activation; immunosuppression; inflammation; interferon; persistent; therapy; virus.

PubMed Disclaimer

Figures

None
Figure 1. The yin-yang of type I interferon signaling. IFN-Is elicit seemingly opposite yet interrelated positive and negative influences on virus replication and dissemination. Throughout the course of viral infection IFN-I is constantly monitoring the virus: immune battle. Upon initial infection, the antiviral and immune-stimulatory (positive) effects of IFN-I predominate, but when virus replication persists due to the host’s inability to clear the infection the immunosuppressive (negative) effects of IFN-I take over, leading to many of the cellular and tissue dysfunctions associated with persistent virus infections and facilitating viral persistence.
See this image and copyright information in PMC

Comment on

References

    1. Pitha PM, et al. Curr Top Microbiol Immunol. 2007;316:41–70. doi: 10.1007/978-3-540-71329-6_4. - DOI - PubMed
    1. Moir S, et al. Annu Rev Pathol. 2011;6:223–48. doi: 10.1146/annurev-pathol-011110-130254. - DOI - PubMed
    1. Jacquelin B, et al. J Clin Invest. 2009;119:3544–55. - PMC - PubMed
    1. Bosinger SE, et al. J Clin Invest. 2009;119:3556–72. - PMC - PubMed
    1. Estes JD, et al. J Immunol. 2008;180:6798–807. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources